<DOC>
	<DOCNO>NCT00448734</DOCNO>
	<brief_summary>This study review safety picoplatin , new type platinum drug , docetaxel , drug commonly use treatment prostate cancer . Patients eligible study diagnosis hormone-refractory prostate cancer metastasize area body , previously treat chemotherapy drug . Picoplatin administer combination docetaxel prednisone identify maximum tolerate dose ( MTD ) . Patients receive IV treatment picoplatin docetaxel every 3 week , prednisone , 5 mg orally , twice daily .</brief_summary>
	<brief_title>A Study Picoplatin Docetaxel Subjects With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate . Radiologic evidence metastatic disease ( JewettWhitmore Stages D1D2 TNM Stage N13 M1 ) . Disease progression recurrence document either : increase serum PSA three consecutive measurement obtain least one week apart , finding radiographic image study . Nonsurgically castrate subject must receive androgen ablation therapy maintenance therapy . Adequate hormonal therapy document castrate level serum testosterone ( subject without surgical castration must serum testosterone less 50 ng/ml ) . At least 4 week must elapse withdrawal antiandrogens ( 6 week case bicalutamide ) . Age 18 year . Subjects older 80 year enter study consider `` physiologically appropriate '' combination chemotherapy . ECOG performance score ( PS ) 0 1 . Stable level pain least 7 day study entry . Life expectancy 3 month . At least 28 day must elapse since prior radiotherapy . At least 28 day must elapse since prior investigational agent . Absolute neutrophil count ( ANC ) least 1.5 x 10^9th/L . Platelet count least 100 x 10^9th/L . Hemoglobin least 10 g/dL . Serum AST ALT level ≥ 1.5 time upper limit normal ( ULN ) . Serum bilirubin ≤ ULN . Serum creatinine ≤ ULN . All subject must agree use appropriate birth control method study 1 month completion study chemotherapy . Prior treatment cytotoxic agent ( except estramustine ) , radioisotopes , biological therapy hormone . Clinical evidence brain leptomeningeal metastasis . Symptomatic peripheral neuropathy Grade 2 high . History another cancer within precede 5 year , except superficial skin cancer . Known hypersensitivity drug formulate Polysorbate 80 . Prior radiotherapy include ≥ 30 % bone marrow ( e.g. , whole pelvis half spine ) . Uncontrolled intercurrent illness ( e.g. , active infection ) . Serious medical psychiatric illness could potentially interfere completion study treatment accord protocol . History serious cardiac disease , define myocardial infarction within six month enrollment , congestive heart failure classify New York Heart Association Class III IV , uncontrolled cardiac arrhythmia , poorly control unstable angina , electrocardiographic evidence acute ischemia .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>metastatic</keyword>
	<keyword>hormone-refractory</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>picoplatin</keyword>
	<keyword>platinum drug</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>docetaxel</keyword>
</DOC>